Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients
- Conditions
- Chronic Hepatitis B
- Interventions
- Registration Number
- NCT02112799
- Lead Sponsor
- Novira Therapeutics, Inc.
- Brief Summary
This Phase 1 trial will assess the dose-related safety and PK profile of different doses of NVR 3-778, first in healthy volunteer subjects (part I) and subsequently in patients with chronic hepatitis B (part II). Additionally, in Part II, changes in patients' serum HBV DNA levels and other virologic efficacy parameters will be assessed.
- Detailed Description
The Part I (Phase 1a) assessments of the dose-related safety and PK of NVR 3-778 in volunteers will be conducted an established Phase 1 unit, which will facilitate the overnight confinements and frequent safety assessments and blood sampling required for the Part I evaluations. The Part II (Phase 1b) assessments of the dose-related safety, PK, and initial antiviral efficacy of NVR 3-778 in hepatitis B patients will also be conducted at approximately 14 different sites to meet enrollment goals of 54-84 chronic hepatitis B patients.
To promote objective safety and tolerance assessments during this trial, study subjects, and site personnel administering the study drug and performing the clinical assessments on the subjects, will be blinded to individual subjects' treatments assignments (active NVR 3-778 or placebo doses), for all treatment cohorts in the study. Study advancement to subsequent volunteer cohorts in Part I and subsequent patient cohorts in Part II will require satisfactory interim reviews of available cumulative safety data by the Part I and Part II Safety Review Committees (SRCs), using the safety criteria and review procedures described in the protocol. Also, there will be two interim reviews of safety data by an independent Safety Monitoring Board (SMB), as described in the protocol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Placebo for NVR 3-778 Placebo for NVR 3-778 Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days NVR 3-778 and Pegasys NVR 3-778 NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days NVR 3-778 and Pegasys Pegasys NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days Pegasys Pegasys Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days NVR 3-778 NVR 3-778 NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
- Primary Outcome Measures
Name Time Method To assess the dose-related safety and tolerability of NVR 3-778 in healthy volunteers and hepatitis B patients Up to 28 days
- Secondary Outcome Measures
Name Time Method